Literature DB >> 15802211

Life-threatening acute adverse cutaneous drug reactions.

Ronni Wolf1, Edith Orion, Batsheva Marcos, Hagit Matz.   

Abstract

Adverse cutaneous reactions to drugs are frequent, affecting 2% to 3% of all hospitalized patients. Fortunately, only about 2% of adverse cutaneous reactions are severe and very few are fatal. Stevens-Johnson syndrome and toxic epidermal necrolysis are severe life-threatening diseases with a mortality rate reaching 30%, and only prompt recognition and diagnosis, withdrawal of the offensive drug, and referral to an intensive care unit or burn care unit might improve the prognosis and save the patient's life. Drug eruption with eosinophilia and systemic symptoms syndrome, formerly termed drug hypersensitivity syndrome, is a rather distinct severe adverse drug reaction (ADR) characterized by eruption, fever, lymph node enlargement, and single or multiple organ involvement, with a high morbidity and a mortality rate of 10%. These severe ADRs, together with serum sickness-like syndrome, are discussed in this review. Other severe reactions, such as anaphylaxis and vasculitis, are discussed elsewhere in this issue. Although most of the readers, particularly those in the outpatient arena, will not be treating these patients, they are the ones who will see them first, diagnose them, realize the potential danger in their condition, and refer them to the appropriate treatment venue. Therefore, dermatologists should be familiar with these conditions and be prepared to handle them adequately.

Entities:  

Mesh:

Year:  2005        PMID: 15802211     DOI: 10.1016/j.clindermatol.2004.06.012

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  34 in total

1.  Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis.

Authors:  Qiancheng Deng; Xia Fang; Qinghai Zeng; Jianyun Lu; Chen Jing; Jinhua Huang
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

2.  Cutaneous side effects of antiosteoporosis treatments.

Authors:  Philippe Musette; Jean-Marc Kaufman; René Rizzoli; Patrice Cacoub; Maria Louisa Brandi; Jean-Yves Reginster
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-02       Impact factor: 5.346

3.  Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study.

Authors:  Agnes L F Chan; Haw Yu Lee; Chi-Hou Ho; Thau-Ming Cham; Shun Jin Lin
Journal:  Curr Ther Res Clin Exp       Date:  2008-04

4.  Acute oromucosal and palmar desquamation: a severe cutaneous adverse reaction to amphotericin and metronidazole.

Authors:  Ryan Connolly; Samantha Russell
Journal:  BMJ Case Rep       Date:  2014-06-12

Review 5.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

6.  Can vitamin B-complex aggravate the carbamazepine induced toxic epidermal necrolysis?

Authors:  Mayuresh V Fegade; Sushama A Bhounsule; Ian Pereira
Journal:  J Clin Diagn Res       Date:  2012-11

Review 7.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

8.  Use and safety profile of antiepileptic drugs in Italy.

Authors:  M L Iorio; U Moretti; S Colcera; L Magro; I Meneghelli; D Motola; A L Rivolta; F Salvo; G P Velo
Journal:  Eur J Clin Pharmacol       Date:  2007-02-16       Impact factor: 2.953

9.  Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?

Authors:  Sophie Bouvresse; Laurence Valeyrie-Allanore; Nicolas Ortonne; Marie Pauline Konstantinou; Sylvia H Kardaun; Martine Bagot; Pierre Wolkenstein; Jean-Claude Roujeau
Journal:  Orphanet J Rare Dis       Date:  2012-09-25       Impact factor: 4.123

10.  HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications.

Authors:  Mayumi Ueta; Katsushi Tokunaga; Chie Sotozono; Hiromi Sawai; Gen Tamiya; Tsutomu Inatomi; Shigeru Kinoshita
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.